Introduction
Elevation of HDL cholesterol, following adenoviral apolipoprotein A-I (apo A-I) gene transfer, may delay or revert ischemic cardiovascular disease, provided transgene expression is persistent. [1] [2] [3] [4] [5] Previously, we demonstrated that gene transfer with an E 1 deleted adenovirus comprising the hepatocyte specific 256 bp human apo A-I promoter, the genomic human apo A-I DNA and four human apo E enhancers (AdA-I.gA-I.4xapoE), was associated with low hepatotoxicity, improved transgene DNA persistence and absence of promoter shut-off resulting in human apo A-I expression above 100 mg/dl for 35 days in C57BL/6 mice. 6 In contrast, gene transfer with a recombinant adenovirus comprising the cytomegalovirus (CMV) promoter/enhancer, the genomic human apo A-I DNA and one or multiple copies of the human apo E enhancer, was associated with major hepatotoxicity, accelerated decline of transgene DNA levels and CMV promoter shut-off, leading to rapid decline of human apo A-I levels. 6 However, no antibodies against human apo A-I were elicited and splenocytes isolated from C57BL/6 mice human apo A-I expression persisted for 6 months in all three strains and no antibodies against human apo A-I occurred in Fvb or Balb/c mice. Human apo A-I transgene DNA level 35 days after transfer with AdA-I.gA-I.4xapoE was 4.6-to 5.5-fold higher than with AdCMV/A-I.gA-I. CMV promoter attenuation occurred in all three strains, but promoter attenuation was not observed in any strain after transfer with AdA-I.gA-I.4xapoE. In conclusion, gene transfer with AdA-I.gA-I.4xapoE is associated with absence of an immune response against human apo A-I, improved transgene DNA persistence and absence of promoter shut-off, resulting in human apo A-I expression for up to 6 months in three different mouse strains. Possibly, the absence of human apo A-I expression in antigen-presenting cells with the liver-specific apo A-I promoter containing construct abrogated the immune response against human apo A-I in Balb/c and Fvb mice. Gene Therapy (2001) 8, 121-127. treated with a human apo A-I adenovirus did not proliferate after addition of human apo A-I in vitro. 6 The absence of an immune response against human apo A-I in C57BL/6 mice is consistent with other reports demonstrating no immune response in this strain against human factor VIII, 7 human factor IX 8 and human ␣ 1 antitrypsin, 9, 10 whereas several other mouse strains are immunized against human proteins. [8] [9] [10] Consequently, the generality of our observations with human apo A-I gene transfer in C57BL/6 mice remained uncertain. Immune responses against foreign proteins may be modulated by the mode of presentation of the antigen to immune cells, and professional antigen presenting cells play a critical role by presenting the antigen to immune cells in the presence of appropriate costimulatory molecules. Jooss et al 11 previously demonstrated that vector mediated transduction of dendritic cells is necessary to elicit a cellular immune response against muscle fibers expressing ␤-galactosidase, explaining absence of immune activation after adeno-associated virus mediated gene transfer of ␤-galactosidase in muscle cells. Pastore et al 12 recently showed that expression of human ␣ 1 -antitrypsin (hAAT) induced by transfer with first generation adenoviral vectors resulted in an antibody response when its cDNA was expressed from the ubiquitous mouse phospoglycerate kinase promoter, but not when expressed from the hepatocyte-specific mouse albumin promoter. Consequently, use of the 256 bp human apo A-I promoter, which is a hepatocyte-specific promoter and does not drive human apo A-I expression by professional antigen-presenting cells, might mitigate an immune response against human apo A-I in mouse strains which, contrary to C57BL/6, are not tolerant for human apo A-I. In the present study, human apo A-I expression from a CMV promoter driven construct and an apo A-I promoter driven construct was compared in three different strains: (C57BL/6, Balb/c and Fvb) in terms of immune response against human apo A-I, transgene DNA persistence and promoter attenuation.
Results
Human apo A-I expression after gene transfer with AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE
The time-course of human apo A-I expression after gene transfer with 5 × 10 8 plaque forming units (p.f.u.) of AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE in C57BL/6 mice is illustrated in Figure 1a . Peak human apo A-I level 6 days after gene transfer with AdCMV/A-I.gA-I in C57BL/6 mice was 52 ± 8.9 mg/dl and human apo A-I level declined to 3.9 ± 1.3 mg/dl at day 35. After gene transfer with AdA-I.gA-I.4xapoE, human apo A-I level at day 35 was 104 ± 8.4 mg/dl and expression was sustained for 6 months.
The time-course of human apo A-I expression after transfer with AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE in Balb/c and Fvb mice is illustrated in Figure 1b and c, respectively. After transfer with AdCMV/A-I.gA-I, peak human apo A-1 expression at day 6 in Balb/c mice (6.2 ± 2.0 mg/dl) was 8.4-fold (P Ͻ 0.01) lower than in C57BL/6 mice and 12-fold lower than in Fvb mice (67 ± 12 mg/dl; P Ͻ 0.01). Human apo A-I levels were below detection limit (1 mg/dl) within 14 days after transfer with AdCMV/A-I.gA-I in Balb/c and Fvb mice, but with AdA-I.gA-I.4xapoE, human apo A-I levels 35 days after gene transfer were 20 ± 3.2 mg/dl and 94 ± 18 mg/dl in Balb/c and Fvb mice, respectively, and expression was sustained for 6 months in both strains.
Effect of promoter choice on humoral immune response against human apo A-I and on human apo A-I induced splenocyte proliferation in vitro A humoral immune response against human apo A-I occurred within 14 days after transfer with AdCMV/A-I.gA-I in Fvb and Balb/c mice, but not in C57BL/6 mice and not after transfer with AdA-I.gA-I.4xapoE in any strain. The geometric means of the titer of antibodies was 1/20 000 (range 1/2000 to 1/64 000) for Balb/c mice and 1/20 000 (range 1/4000 to 1/128 000) for Fvb mice. To investigate the role of these antibodies in the accelerated decline of human apo A-I levels in Fvb mice, human apo A-I transgenic Fvb mice expressing low levels of human apo A-I (9.5 ± 0.58 mg/dl) were injected with 5 × 10 
u. of AdCMV/A-I.gA-I (closed symbols) and AdA-I.gA-I.4xapoE (open symbols); (a) in C57BL/6 mice (, ᮀ); (b) in Balb/c mice (᭹, ᭺) and (c) in Fvb mice (̆, ̅) and in Fvb human apo A-I transgenic mice (᭜).
human apo A-I levels in human apo A-I transgenic Fvb mice (data not shown).
Immunological responses against blood-borne antigens are likely to be elicited in the spleen, whereas macrophages in the liver filter antigens, but in general do not provoke an immunological response. To investigate the potential role of human apo A-I expression by antigen presenting cells in the humoral immune response against human apo A-I, human apo A-I expression 3 days after transfer with AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE in Fvb mice was studied by real-time PCR in the spleen, which contains numerous antigen presenting B-lymphocytes and professional antigen presenting dendritic cells. No human apo A-I expression was observed after transfer with AdA-I.gA-I.4xapoE (n = 4), consistent with the hepatocyte specificity of the 256 bp apo A-I promoter. In contrast, human apo A-I expression (0.021 ± 0.0032; n = 4) was detected after transfer with AdCMV/A-I.gA-I.
To evaluate an effective immune response against human apo A-I in the spleen after transfer with AdCMV/A-I.gA-I in Balb/c and Fvb mice, ex vivo splenocyte proliferation induced by 6.25 g/ml of human apo A-I was investigated. T cell proliferation induced by human apo A-I antigen in vitro occurred in Balb/c and Fvb mice after gene transfer with AdCMV/A-I.gA-I, but not after transfer with AdA-I.gA-I.4xapoE (Table 1) . As a positive control, T cell proliferation induced by the recombinant control adenovirus AdRR5 added at a multiplicity of infection of 25 in vitro was investigated. T cell proliferation occurred after gene transfer with both viruses in all three strains (Table 1) .
Accelerated decline of transgene DNA within the first 3 days in Balb/c mice and improved DNA persistence after transfer with AdA-I.gA-I.4xapoE compared with AdCMV/A-I.gA-I in all three strains Human apo A-I transgene DNA copy-numbers per diploid genome in the liver 10 min, 24 h, 3 days, 6 days and 35 days after gene transfer with AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE are summarized in Table 2 . No significant differences of human apo A-I DNA copy number occurred 10 min after gene transfer, indicating that the same dose of virus had been administered.
Human apo A-I DNA copy number 24 h after gene transfer of AdCMV/A-I.gA-I in Balb/c mice was 2.6-fold (P Ͻ 0.05) and 3.2-fold (P Ͻ 0.05) lower than after transfer in C57BL/6 and Fvb mice, respectively, and this difference persisted at later time-points. 
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Human apo A-I DNA copy number 3 days after gene transfer of AdA-I.gA-I.4xapoE in Balb/c mice was 2.6-fold (P Ͻ 0.05) and 3.2-fold (P Ͻ 0.05) lower than after transfer in C57BL/6 and Fvb mice, respectively. Lower human apo A-I transgene DNA copy numbers in Balb/c mice after gene transfer with AdA-I.gA-I.4xapoE persisted until day 35.
Human apo A-I DNA copy number 35 days after transfer with AdA-I.gA-I.4xapoE in C57BL/6, Balb/c and Fvb mice was 5.5-fold (P Ͻ 0.05), 5.2-fold (P Ͻ 0.05) and 4.6-fold (P Ͻ 0.05), respectively, higher than after transfer with AdCMV/A-I.gA-I.
Promoter attenuation occurs after gene transfer with AdCMV/A-I.gA-I, but not after transfer with AdA-I.gA-I.4xapoE
The human apo A-I mRNA levels normalized versus GAPDH and the human apo A-I mRNA/DNA ratio in the liver are indicated in Tables 3 and 4 , respectively.
Human apo A-I mRNA after transfer with AdCMV/A-I.gA-I declined 15-fold (P Ͻ 0.05) and 11-fold (P Ͻ 0.05) between day 6 and day 35 in C57BL/6 and Fvb mice, respectively, and was below detection limit (0.001) 35 days after transfer in Balb/c mice ( Table 2) . The human apo A-I mRNA/DNA ratio after transfer with AdCMV/A-I.gA-I declined 3.6-fold (P Ͻ 0.05), respectively, 2.8-fold (P Ͻ 0.05) between day 6 and day 35 in C57BL/6 and Fvb mice (Table 3) , indicating CMV promoter attenuation.
Human apo A-I mRNA after transfer with AdA-I.gA-I.4xapoE increased 3.5-fold (P Ͻ 0.05) between day 6 and day 35 in Balb/c mice and was not significantly altered between day 6 and day 35 in C57BL/6 and Fvb mice. Human apo A-I mRNA 35 days after gene transfer with AdA-I.gA-I.4xapoE was 26-fold (P Ͻ 0.05) and 11-fold (P Ͻ 0.05) higher in C57BL/6 and Fvb mice, respectively, Figure 2 . Serum levels of ALT were at least three-fold higher (P Ͻ 0.05) between day 6 and day 21 after transfer with AdCMV/A-I.gA-I than with AdA-I.gA-I.4xapoE in all three strains. ALT levels after transfer with AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE were more than two-fold higher (P Ͻ 0.05) between day 6 and day 35 in Fvb mice than in C57BL/6 and Balb/c mice. To exclude that differences in the number of administered particles underly differences of hepatotoxicity after gene transfer with AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE, the particle concentration of both batches was determined and the particle to p.f.u. ratio was calculated. This ratio was 72 and 77 for AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE, respectively.
Discussion
The main findings of the present study are that (1) a humoral immune response against human apo A-I leads to undetectable human apo A-I levels within 14 days in Fvb and Balb/c mice after transfer with a CMV promoter driven construct, but no antibodies are detected after transfer with an apo A-I promoter driven construct; (2) gene transfer with an apo A-I promoter driven construct is associated with significantly lower hepatotoxicity in all three strains, although significant differences of hepatotoxicity also exist between different strains; (3) improved DNA persistence, absence of an immune response against human apo A-I and absence of promoter shut-off leads to sustained expression of human apo A-I after transfer with AdA-I.gA-1.4xapoE for 6 months in all three strains.
We have previously demonstrated that C57BL/6 mice are tolerant for human apo A-I, consistent with other reports demonstrating no immune response in this strain against human factor VIII, 7 human factor IX 8 and human ␣ 1 anti-trypsin, 9 ,10 whereas several other mouse strains can induce an immune response against these human proteins. [8] [9] [10] Both Fvb and Balb/c mice mounted a humoral immune response against human apo A-I after transfer with AdCMV/A-I.gA-I and human apo A-I was undetectable within 14 days. Because human apo A-I mRNA levels 35 days after gene transfer were not lower in Fvb mice than in C57BL/6 mice, the absence of detectable human apo A-I in Fvb mice is likely to be due to immune complex formation, which may lead to accelerated catabolism in the reticulo-endothelial system or may block the detection of human apo A-I by the ELISA. 8 The causal role of these antibodies in the rapid disappearance of human apo A-I in Fvb mice after transfer with AdCMV/A-I.gA-I is demonstrated by the significantly higher human apo A-I levels in human apo A-I transgenic Fvb mice 35 days after transfer compared with baseline levels.
Gene transfer with an apo A-I promoter driven adenoviral construct does not induce a humoral immune response in Fvb or Balb/c mice. Endocytosis of human apo A-I after secretion by antigen presenting cells may lead to 'endogenous' antigen presentation by class II molecules to CD4 + cells, which may be much more efficient than presentation of circulating human apo A-I as an exogenous antigen. 13 Because the 256 bp human apo A-I promoter is hepatocyte-specific, absence of human apo A-I expression by professional antigen-presenting cells may abrogate an immune response against human 
4xapoE (open symbols); (a) in C57BL/6 mice (,ᮀ); (b) in Balb/c mice (᭹,᭺) and (c) in Fvb mice (̆,̅) and in Fvb human apo A-I transgenic mice (᭜).
apo A-I in Fvb and Balb/c mice. This hypothesis is corroborated by data in this study demonstrating human apo A-I expression in the spleen, which contains numerous antigen presenting cells, and human apo A-I induced splenocyte proliferation in vitro after transfer with AdCMV/A-I.gA-I, but not after transfer with AdA-I.gA-I.4xapoE.
Jooss et al 11 previously demonstrated that vectorGene Therapy mediated transduction of dendritic cells is necessary to elicit a cellular immune response against muscle fibers expressing ␤-galactosidase, explaining the absence of immune activation after adeno-associated virus mediated gene transfer of ␤-galactosidase in muscle cells. Pastore et al 12 recently showed that expression of human ␣ 1 -antitrypsin (hAAT) induced by transfer with first generation adenoviral vectors resulted in an antibody response to hAAT when its cDNA was expressed from the ubiquitous mouse phosphoglycerate kinase promoter, but not when expressed from the hepatocyte-specific mouse albumin promoter. In aggregate, these data suggest that use of a tissue specific promoter may be beneficial to eliminate an immune response against the transgene product after gene transfer.
We have previously demonstrated improved transgene DNA persistence after gene transfer with apo A-I promoter driven constructs in C57BL/6 mice. 6 In the present study, these findings are extended to Balb/c and Fvb mice. Surprisingly, human apo A-I transgene DNA levels in Balb/c mice were significantly lower than in C57BL/6 or Fvb mice within 24 h after gene transfer with AdCMV/A-I.gA-I and within 3 days after transfer with AdA-I.gA-I.4xapoE. Early DNA loss has previously been attributed to an innate immune response and could be partially inhibited by silica administration before gene transfer, indicating a role of Kupffer cells in early DNA loss.
14 The present findings, demonstrating significant differences in early DNA loss after adenoviral gene transfer in different inbred mouse strains, indicate that significant variation in transgene DNA levels and thus expression may occur after adenoviral gene transfer in outbred animals.
Hepatotoxicity was significantly higher in Fvb mice than in C57BL/6 mice and Balb/c mice, both after gene transfer with AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE. Because toxicity is strongly dose-dependent, 15 low hepatotoxicity after transfer in Balb/c mice may be related to accelerated loss of DNA in the first 3 days, leading to significantly lower viral DNA and correspondingly lower liver injury at later time-points. Higher toxicity in Fvb mice than in C57BL/6 mice after transfer with AdCMV/A-I.gA-I is not related to a cellular immune response against human apo A-I expressing cells, because toxicity in Fvb mice was not significantly different than after transfer in Fvb human apo A-I transgenic mice, that are tolerant for human apo A-I.
In conclusion, gene transfer with AdA-I.gA-I.4xapoE is associated with absence of an immune response against human apo A-I, improved DNA persistence and absence of promoter shut-off resulting in human apo A-I expression for up to 6 months in three different mouse strains.
Materials and methods

Generation of recombinant adenoviruses
The construction and generation of AdCMV/A-I.gA-I and AdA-I.gA-I.4xapoE have been described previously. 6 AdCMV/A-I.gA-I contains the 760 bp cytomegalovirus promoter/enhancer (CMV) followed by the 256 bp apo A-I promoter (A-I), the genomic apo A-I sequence (gA-I) and the SV40 splice/polyadenylation site. AdA-I.gA-I.4xapoE contains the 256 bp apo A-I promoter in front of the ge-nomic human apo A-I sequence, four copies of the human apo E enhancer and the SV40 splice polyadenylation site. The AdRR5 control virus has been described previously. 6 Titers were calculated by determining plaque forming units (p.f.u.) as described previously. 6 The viral particle concentration was calculated by measuring the optical density of the viral DNA content. 16 Animal experiments All experimental procedures in animals were performed in accordance with protocols approved by the Institutional Animal Care and Research Advisory Committee. Recombinant adenoviruses were administered by tail vein injection into female C57BL/6 mice, Balb/c or Fvb mice. Each viral dose was given in a final volume of 300 l. Experimental groups consisted of at least 10 animals for each recombinant virus, viral dose and strain. Blood was obtained by puncture of the retro-orbital plexus of at least five animals at each time-point for each group. Anticoagulation was performed with 1/10 volume of 4% trisodiumcitrate and plasma was obtained by centrifugation at 3000 r.p.m. for 10 min.
Human apo A-I ELISA Human apo A-I levels were determined by sandwich ELISA. Briefly, polystyrene microtiter plates (Elscolab, Kruisbeke, Belgium) were coated with a rabbit antihuman apo A-I polyclonal antibody. Diluted plasma samples (1:25 000; 1:50 000; 1:100 000; 1:200 000) were added to the wells for 2 h. After washing, a 1:15 000 dilution of the murine monoclonal antibody A 4 H 4 A 7 conjugated with peroxidase was added to the wells for 2 h. Peroxidase reaction was performed by adding H 2 O 2 and ortho-phenylene-diamine. Finally, absorbance was measured at 492 nm.
Detection of human apo A-I antibodies by ELISA Human apo A-I antibodies were determined as described previously. 6 Briefly, polystyrene microtiter plates (Elscolab) were coated with 0.14 m of human apo A-I or 0.14 m of human tissue-type plasminogen activator (t-PA), which was used as control antigen. Dilutions of plasma samples up to 1:128 000 were added to the wells for 2 h. After washing of the plates, rabbit anti-mouse polyclonal antibodies conjugated with peroxidase were diluted 1:10 000 and added to the wells for 2 h. Peroxidase reaction was performed with H 2 O 2 and ortophenylenediamine and absorbance was measured at 492 nm. The titer of antibodies was defined as the plasma dilution for which the optical density of the antibody assay was higher than 0.100, which is significantly above background.
T cell proliferation assay in vitro Spleen cells were isolated from control mice and from mice 21 days after gene transfer with 5 × 10 8 p.f.u. of AdA-I.gA-I.4xapoE or AdCMV.A-I.gA-I. Cells were plated into 96 well U-bottom polystryene plates (Elscolab) at 200 000 cells per well and were cultured in RPMI-1640 medium (Life Technologies, Merelbeke, Belgium) supplemented with 10% fetal bovine serum (Life Technologies) for 6 days in the presence of 6.25 g/ml human apo A-I, in the presence of the AdRR5 controlvirus at a multiplication of infection of 25 or in the absence of antigen. To assay proliferation, 1 Ci/well of 3 H-thymidine (ICN Biomedicals, Asse-Relegem, Belgium) was added to each well. After 8 h of incubation, cells were harvested and incorporated radioactivity was determined by a ␤-counter (Packard Instrument Co., Meriden, CT, USA). All experiments were performed in quadruplicate and results are expressed as stimulation index (incorporated radioactivity in the presence of antigen/ incorporated radioactivity in the absence of antigen).
Quantification of human apo A-I transgene DNA in the liver Liver tissue was lysed overnight at 50°C in 1 ml of lysis buffer containing 100 mm Tris.HCI, pH 8.8, 200 mm NaCI, 5 mm EDTA, 0.2% sodium dodecyl sulphate, 0.01 g/% proteinase K (Roche, Brussels, Belgium) as described previously. 6 DNA was obtained by phenol:-chloroform:isoamylalcohol extraction. Human apo A-I DNA was quantified using quantitative real-time PCR and the human apo A-I DNA copy number was normalized to the copy number of the prion protein (PrP) housekeeping gene. Human apo A-I primers and probes anneal to exon 3. Murine PrP primers and probes anneal to exon I. All primers and probes were designed using the computer program Primer Express and sequences are represented in Table 5 .
Quantification of human apo A-I mRNA in the liver Total RNA was isolated from mouse liver using TRIzol Reagent (Life Technologies). RNA (10 g) was treated with DNAse (Pharmacia, Roosendal, Netherlands) and subsequently reverse transcribed using Superscript II RT (Life Technologies) at 42°C for 50 min in the presence of 0.5 mm dNTPs, 0.01 m DTT, 1× first strand buffer and 250 ng pd(N) 6 Random Hexamer (Pharmacia). Human apo A-I cDNA was measured using quantitative real-time PCR and the human apo A-I cDNA copy number was normalized to the copy number of the glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) housekeeping gene. Hapo A-I, human apo A-I; PrP, prion protein; GAPDH, glyceraldehyde-3-phosphate-dehydrogenase. a cDNA: all DNA sequences were obtained from the Genebank database.
